Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort

BACKGROUND/PURPOSE: Studies have demonstrated that rheumatoid arthritis (RA) patients who achieve low disease activity or remission are able to taper biological disease-modifying antirheumatic drugs (bDMARDs). The aim of this study was to evaluate the proportion of patients in whom bDMARDs can be ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dierckx, Stéphanie, Sokolova, Tatiana, Lauwerys, Bernard R., Avramovska, Aleksandra, de Bellefon, Laurent Meric, Toukap, Adrien Nzeusseu, Stoenoiu, Maria, Houssiau, Frédéric A., Durez, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189594/
https://www.ncbi.nlm.nih.gov/pubmed/32345367
http://dx.doi.org/10.1186/s13075-020-02165-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189594/
https://www.ncbi.nlm.nih.gov/pubmed/32345367
http://dx.doi.org/10.1186/s13075-020-02165-4

Ejemplares similares